Nasdaq
$25.43▲ 0.04%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $295.3MShares out 11.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
13- 2d agoAfter-hours26.10.23 05:484Ownership#●●●
Surrozen, Inc./DE
Entities affiliated with The Column Group, including insiders and major shareholders of Surrozen, Inc., reported changes in their beneficial ownership of securities as of October 20, 2026. This filing provides the details of the insider equity transactions via Form 4.…more
$25.43+0.04%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 2d agoAfter-hours26.10.23 05:45SCHEDULE 13D/AOwnership
Surrozen, Inc./DE
Column Group III GP, LP has filed a SCHEDULE 13D/A regarding its beneficial ownership in Surrozen, Inc. This filing serves to formally update the status of the investor's equity holdings in the company.…more
$25.43+0.04%vs prev closeView filingShare - 2d agoAfter-hours26.10.23 05:454Ownership
Surrozen, Inc./DE
Surrozen, Inc. insider Tim Kutzkey reported a change in beneficial ownership of company securities effective October 20, 2026. This filing serves as an official disclosure to the SEC regarding the insider's updated share holdings.…more
$25.43+0.04%vs prev closeView filingShare
12 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoAfter-hours26.10.21 05:59Bullish#●●●#●●●#●●●
Surrozen Closes $95.1 Million Private Placement
Surrozen has completed the second tranche of its private placement, raising $95.1 million to extend its cash runway into 2029. The proceeds will support the clinical advancement of its ophthalmic pipeline candidates, SZN-8141 and SZN-8143.…more
$25.43+0.04%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.2Pre-market26.10.02 21:00
●●●●●●●● ●●●●● ●●●●●●
Surrozen has received FDA clearance for its IND application for SZN-8141, a treatment for diabetic macular edema, enabling the start of clinical trials. This milestone triggers the second closing of a private placement, providing the company with approximately $95.1 million in gross proceeds.…more
$25.43+0.04%vs prev close - 9.24Regular26.09.25 00:41
●●●●●●●● ●●●●● ●●●●●●
Surrozen has submitted an Investigational New Drug application to the FDA for its diabetic macular edema treatment, SZN-8141. While this marks a step toward clinical trials, initial results are not expected until the second half of 2027.…more
$25.43+0.04%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report